Virulence blockers as alternatives to antibiotics: Type III secretion inhibitors against Gram-negative bacteria

Journal of Internal Medicine

Volumn 264, Issue 1, 2008, Pages 17-29

  Keyser, P ^a   Elofsson, M ^b   Rosell, S ^a   Wolf Watz, H ^b  

^a Innate Pharmaceuticals AB   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Antibiotic resistance; Type III secretion system; Virulence blockers

Indexed keywords

ANTIBIOTIC AGENT; HYDRAZIDE DERIVATIVE;

BACTERIAL VIRULENCE; CARDIOVASCULAR DISEASE; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CYSTIC FIBROSIS; CYTOSOL; DIARRHEA; EX VIVO STUDY; GASTROINTESTINAL DISEASE; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HOST CELL; HUMAN; IN VITRO STUDY; LUNG INFECTION; NONHUMAN; PATHOGENESIS; PLAGUE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SALMONELLA; SALMONELLOSIS; SCREENING; SEXUALLY TRANSMITTED DISEASE; SHIGELLOSIS; TRACHOMA; TUBERCULOSIS; TYPHOID FEVER; YERSINIA;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; VIRULENCE; VIRULENCE FACTORS;

EID: 44949215750     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.01941.x     Document Type: Review

References (64)

1. Ash C. Antibiotic resistance: the new apocalypse? Trends Microbiol 1996 4 : 371 2.
2. Overbye KM, Barrett JF. Antibiotics: where did we go wrong? Drug Discov Today 2005 10 : 45 52.
3. America IDSo. Bad bugs, no drugs [WWW document]. URL http://wwwidsociety. org/WorkArea/showcontent.aspx?id=5554 2004. Last access date: 29 February 2008.
4. Chan PF, Macarron R, Payne DJ, Zalacain M, Holmes DJ. Novel antibacterials: a genomics approach to drug discovery. Curr Drug Targets Infect Disord 2002 2 : 291 308.
5. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007 6 : 29 40.
6. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004 10 : S122 9.
7. Marra CM, Colina AP, Godornes C et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. J Infect Dis 2006 194 : 1771 3.
8. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007 3 : 541 8.
9. Finlay BB, Falkow S. Common themes in microbial pathogenicity revisited. Microb Mol Biol Rev 1997 16 : 136 69.
10. Salyers AA, Whitt DD. Bacterial Pathogenesis; A Molecular Approach. 2002. Washington : ASM Press, American Society for Microbiology.
11. Cornelis GR, Van Gijsegem F. Assembly and function of type III secretory systems. Annu Rev Microbiol 2000 54 : 735 74.
12. Cornelis GR. Yersinia type III secretion: send in the effectors. J Cell Biol 2002 158 : 401 8.
13. Kubori T, Matsushima Y, Nakamura D et al. Supramolecular structure of the Salmonella typhimurium type III protein secretion system. Science 1998 280 : 602 5.
14. Sekiya K, Ohishi M, Ogino T, Tamano K, Sasakawa C, Abe A. Supermolecular structure of the enteropathogenic Escherichia coli type III secretion system and its direct interaction with the EspA-sheath-like structure. Proc Natl Acad Sci U S A 2001 98 : 11638 43.
15. He SY, Jin Q. The Hrp pilus: learning from flagella. Curr Opin Microbiol 2003 6 : 15 9.
16. Rosqvist R, Magnusson KE, Wolf-Watz H. Target cell contact triggers expression and polarized transfer of Yersinia YopE cytotoxin into mammalian cells. EMBO J 1994 13 : 964 72.
17. Cornelis GR, Wolf-Watz H. The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells. Mol Microbiol 1997 23 : 861 7.
18. Bolin I, Portnoy DA, Wolf-Watz H. Expression of the temperature-inducible outer membrane proteins of yersiniae. Infect Immun 1985 48 : 234 40.
19. Hakansson S, Schesser K, Persson C et al. The YopB protein of Yersinia pseudotuberculosis is essential for the translocation of Yop effector proteins across the target cell plasma membrane and displays a contact-dependent membrane-disrupting activity. EMBO J 1996 15 : 5812 23.
20. Rosqvist R, Skurnik M, Wolf-Watz H. Increased virulence of Yersinia pseudotuberculosis by two independent mutations. Nature 1988 334 : 522 4.
21. Fallman M, Persson C, Schesser K, Wolf-Watz H. Bidirectional signaling between Yersinia and its target cell. Folia Microbiol (Praha) 1998 43 : 263 73.
22. Von Pawel-Rammingen U, Telepnev MV, Schmidt G, Aktories K, Wolf-Watz H, Rosqvist R. GAP activity of the Yersinia YopE cytotoxin specifically targets the Rho pathway: a mechanism for disruption of actin microfilament structure. Mol Microbiol 2000 36 : 737 48.
23. Navarro L, Koller A, Nordfelth R, Wolf-Watz H, Taylor S, Dixon JE. Identification of a molecular target for the Yersinia protein kinase A. Mol Cell 2007 26 : 465 77.
24. Schesser K, Spiik AK, Dukuzumuremyi JM, Neurath MF, Pettersson S, Wolf-Watz H. The yopJ locus is required for Yersinia-mediated inhibition of NF-kappaB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity. Mol Microbiol 1998 28 : 1067 79.
25. Mukherjee S, Keitany G, Li Y et al. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 2006 312 : 1211 4.
26. Walsh C. Where will new antibiotics come from? Nat Rev Microbiol 2003 1 : 65 70.
27. Fernandes P. Antibacterial discovery and development - the failure of success? Nat Biotechnol 2006 24 : 1497 503.
28. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005 4 : 206 20.
29. Wilson RM, Danishefsky SJ. Small molecule natural products in the discovery of therapeutic agents: the synthesis connection. J Org Chem 2006 71 : 8329 51.
30. Nosocomial enterococci resistant to vancomycin, United States 1989-1993. MMWR Morb Mortal Wkly Rep. 1993 42 : 597 9.
31. Speert DP, Campbell ME, Davidson AG, Wong LT. Pseudomonas aeruginosa colonization of the gastrointestinal tract in patients with cystic fibrosis. J Infect Dis 1993 167 : 226 9.
32. Burns JL, Gibson RL, McNamara S et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001 183 : 444 52.
33. Niyogi SK. Increasing antimicrobial resistance-an emerging problem in the treatment of shigellosis. Clin Microbiol Infect 2007 13 : 1141 3.
34. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986 315 : 161 8.
35. Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis 1985 151 : 832 9.
36. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000 181 (Suppl. 3 S402 10.
37. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995 8 : 451 61.
38. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988 2 : 983 6.
39. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993 167 : 841 9.
40. Kasi PM, Gilani AI, Ahmad K, Janjua NZ. Blinding trachoma: a disease of poverty. PLoS Med 2004 1 : e44.
41. Horner PJ, Crowley T, Leece J, Hughes A, Smith GD, Caul EO. Chlamydia trachomatis detection and the menstrual cycle. Lancet 1998 351 : 341 2.
42. Hansen-Wester I, Hensel M. Salmonella pathogenicity islands encoding type III secretion systems. Microbes Infect 2001 3 : 549 59.
43. Collazo CM, Galan JE. The invasion-associated type-III protein secretion system in Salmonella- a review. Gene 1997 192 : 51 9.
44. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005 366 : 749 62.
45. Quinn T, O'Mahony R, Baird AW, Drudy D, Whyte P, Fanning S. Multi-drug resistance in Salmonella enterica: efflux mechanisms and their relationships with the development of chromosomal resistance gene clusters. Curr Drug Targets 2006 7 : 849 60.
46. Woo YK, Lee SH. Genetic diversity of multi-resistant Salmonella enterica serotype Typhimurium isolates from animals and humans. J Microbiol 2006 44 : 106 12.
47. Kauppi AM, Nordfelth R, Hagglund U, Wolf-Watz H, Elofsson M. Salicylanilides are potent inhibitors of type III secretion in Yersinia. Adv Exp Med Biol 2003 529 : 97 100.
48. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol 2003 10 : 241 9.
49. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M. Small-molecule inhibitors specifically targeting type III secretion. Infect Immun 2005 73 : 3104 14.
50. Bailey L, Gylfe A, Sundin C et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett 2007 581 : 587 95.
51. Muschiol S, Bailey L, Gylfe A et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 2006 103 : 14566 71.
52. Slepenkin A, Enquist PA, Hagglund U, de la Maza LM, Elofsson M, Peterson EM. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun 2007 75 : 3478 89.
53. Hudson DL, Layton AN, Field TR et al. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob Agents Chemother 2007 51 : 2631 5.
54. Negrea A, Bjur E, Ygberg SE, Elofsson M, Wolf-Watz H, Rhen M. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2007 51 : 2867 76.
55. Wolf K, Betts HJ, Chellas-Gery B, Hower S, Linton CN, Fields KA. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol 2006 61 : 1543 55.
56. Gauthier A, Robertson ML, Lowden M, Ibarra JA, Puente JL, Finlay BB. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob Agents Chemother 2005 49 : 4101 9.
57. Pan N, Lee C, Goguen J. High throughput screening for small-molecule inhibitors of type III secretion in Yersinia pestis. Adv Exp Med Biol 2007 603 : 367 75.
58. Zarivach R, Vuckovic M, Deng W, Finlay BB, Strynadka NC. Structural analysis of a prototypical ATPase from the type III secretion system. Nat Struct Mol Biol 2007 14 : 131 7.
59. Dahlgren M, Kauppi AM, Olsson I-M, Linusson A, Elofsson M. Design, synthesis, and multivariate quantitative structure-activity relationships of salicylanilides - potent inhibitors of type III secretion in Yersinia. J Med Chem 2007 50 : 6177 88.
60. Kauppi AM, Andersson CD, Norberg HA, Sundin C, Linusson A, Elofsson M. Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides. Bioorg Med Chem 2007 15 : 6994 7011.
61. Linington RG, Robertson M, Gauthier A, Finlay BB, van Soest R, Andersen RJ. Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Org Lett 2002 4 : 4089 92.
62. Linington RG, Robertson M, Gauthier A et al. Caminosides B-D, antimicrobial glycolipids isolated from the marine sponge Caminus sphaeroconia. J Nat Prod 2006 69 : 173 7.
63. Tsuchiya S, Sunazuka T, Hirose T et al. Asymmetric total synthesis of (+)-K01-0509 B: determination of absolute configuration. Org Lett 2006 8 : 5577 80.
64. Jiansong Sun XH, Biao Yu. First total synthesis of caminoside A, an antibmicrobial glycolipid from sponge. Synlett 2005 ?? : 437 40.